Literature DB >> 8774407

Motivational deficits after brain injury: effects of bromocriptine in 11 patients.

J H Powell1, S al-Adawi, J Morgan, R J Greenwood.   

Abstract

OBJECTIVE: To test the hypothesis that treatment with bromocriptine would ameliorate deficits in clinical motivation, responsiveness to reward, and frontal cognitive function after brain injury.
METHOD: An open trial in six men and five women who had had either traumatic brain injury or subarachnoid haemorrhage between two months and five years previously. After repeated baseline assessments, bromocriptine was given in gradually increasing doses. Assessments were repeated at increasing doses, during maintenance, and after withdrawal. Novel structured instruments for quantifying motivation were developed; measures of anxiety and depression, and cognitive tests sensitive to motivation or frontal lobe involvement were also given.
RESULTS: Bromocriptine treatment was followed by improved scores on all measures other than mood. Improvement was maintained after bromocriptine withdrawal in eight of the patients.
CONCLUSION: Poor motivation in patients with brain injury may result from dysfunction in the mesolimbic/mesocortical dopaminergic circuitry, giving rise to associated deficiencies in reward responsiveness and frontal cognitive function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774407      PMCID: PMC1073895          DOI: 10.1136/jnnp.60.4.416

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  28 in total

Review 1.  Catecholamine theories of reward: a critical review.

Authors:  R A Wise
Journal:  Brain Res       Date:  1978-08-25       Impact factor: 3.252

2.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

3.  Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists.

Authors:  E D Ross; R M Stewart
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

4.  Clinical use of amantadine in brain injury rehabilitation.

Authors:  J L Nickels; W N Schneider; M L Dombovy; T M Wong
Journal:  Brain Inj       Date:  1994 Nov-Dec       Impact factor: 2.311

Review 5.  The involvement of nucleus accumbens dopamine in appetitive and aversive motivation.

Authors:  J D Salamone
Journal:  Behav Brain Res       Date:  1994-04-18       Impact factor: 3.332

6.  Organization of catecholamine neurons projecting to the frontal cortex in the rat.

Authors:  O Lindvall; A Björklund; I Divac
Journal:  Brain Res       Date:  1978-02-17       Impact factor: 3.252

7.  A double-blind cross-over placebo-controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinson's disease.

Authors:  R.A. Weddell; R. Weiser
Journal:  Behav Pharmacol       Date:  1995-01       Impact factor: 2.293

8.  N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury.

Authors:  R Van Reekum; M Bayley; S Garner; I M Burke; S Fawcett; A Hart; W Thompson
Journal:  Brain Inj       Date:  1995-01       Impact factor: 2.311

9.  Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat.

Authors:  D F Fiorino; A Coury; H C Fibiger; A G Phillips
Journal:  Behav Brain Res       Date:  1993-06-30       Impact factor: 3.332

10.  The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician.

Authors:  H S Levin; W M High; K E Goethe; R A Sisson; J E Overall; H M Rhoades; H M Eisenberg; Z Kalisky; H E Gary
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-02       Impact factor: 10.154

View more
  28 in total

1.  Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.

Authors:  Laura B Zahodne; Michael Marsiske; Michael S Okun; Ramon L Rodriguez; Irene Malaty; Dawn Bowers
Journal:  Neuropsychology       Date:  2011-12-05       Impact factor: 3.295

2.  Dopamine agonists can improve pure apathy associated with lesions of the prefrontal-basal ganglia functional system.

Authors:  Carlo Blundo; Carmela Gerace
Journal:  Neurol Sci       Date:  2015-01-21       Impact factor: 3.307

3.  High Behavioral Approach System (BAS) sensitivity, reward responsiveness, and goal-striving predict first onset of bipolar spectrum disorders: a prospective behavioral high-risk design.

Authors:  Lauren B Alloy; Rachel E Bender; Wayne G Whitehouse; Clara A Wagner; Richard T Liu; David A Grant; Shari Jager-Hyman; Ashleigh Molz; James Y Choi; Eddie Harmon-Jones; Lyn Y Abramson
Journal:  J Abnorm Psychol       Date:  2011-10-17

Review 4.  A cognitive neuroscience approach to individual differences in sensitivity to reward.

Authors:  C Avila; M A Parcet; A Barrós-Loscertales
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

5.  Revamping neurorehabilitation in Oman.

Authors:  S Al-Adawi; D T Burke
Journal:  J Sci Res Med Sci       Date:  2001-10

6.  Dopamine D2-receptor-mediated increase in vascular and endothelial NOS activity ameliorates cerebral vasospasm after subarachnoid hemorrhage in vitro.

Authors:  Gail J Pyne-Geithman; Danielle N Caudell; Matthew Cooper; Joseph F Clark; Lori A Shutter
Journal:  Neurocrit Care       Date:  2008-09-20       Impact factor: 3.210

7.  Feeling cold: an unusual brain injury symptom and its treatment with vasopressin.

Authors:  P Eames
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

8.  Abulia following an episode of cardiac arrest.

Authors:  Vismay Dinesh Naik
Journal:  BMJ Case Rep       Date:  2015-07-01

9.  Responsiveness to reward following cessation of smoking.

Authors:  Sarah Snuggs; Peter Hajek
Journal:  Psychopharmacology (Berl)       Date:  2012-09-25       Impact factor: 4.530

10.  Deficits in discrimination after experimental frontal brain injury are mediated by motivation and can be improved by nicotinamide administration.

Authors:  Cole Vonder Haar; William R Maass; Eric A Jacobs; Michael R Hoane
Journal:  J Neurotrauma       Date:  2014-08-21       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.